What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Ursula A. Matulonis mainly investigates Internal medicine, Ovarian cancer, Oncology, Chemotherapy and Cancer.
Her studies deal with areas such as Surgery, Olaparib and Gastroenterology as well as Internal medicine.
Her Olaparib study integrates concerns from other disciplines, such as Interim analysis, PARP inhibitor, Maintenance therapy, Gynecology and Hazard ratio.
The various areas that Ursula A. Matulonis examines in her Ovarian cancer study include Bevacizumab, Cancer research, Pharmacology and DNA repair.
Ursula A. Matulonis combines subjects such as Cediranib, Clinical trial, Serous fluid and Pembrolizumab with her study of Oncology.
Her research integrates issues of Taxane, Anemia and Toxicity in her study of Chemotherapy.
Her most cited work include:
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. (1098 citations)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (954 citations)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (954 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Internal medicine, Oncology, Ovarian cancer, Cancer research and Chemotherapy.
Her Internal medicine study incorporates themes from Surgery and Olaparib.
Her Olaparib research incorporates elements of BRCA mutation and PARP inhibitor.
As part of one scientific family, Ursula A. Matulonis deals mainly with the area of Oncology, narrowing it down to issues related to the Platinum sensitive, and often Serous ovarian cancer.
Her Ovarian cancer research is multidisciplinary, incorporating perspectives in Cediranib, Adverse effect, Serous fluid, Gynecology and Disease.
Her Chemotherapy research integrates issues from Gastroenterology, Regimen and Taxane.
She most often published in these fields:
- Internal medicine (60.00%)
- Oncology (48.74%)
- Ovarian cancer (49.90%)
What were the highlights of her more recent work (between 2017-2021)?
- Ovarian cancer (49.90%)
- Cancer research (28.74%)
- Internal medicine (60.00%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Ovarian cancer, Cancer research, Internal medicine, Oncology and PARP inhibitor.
The study incorporates disciplines such as Bevacizumab, Serous fluid, Paclitaxel and Olaparib in addition to Ovarian cancer.
Her Olaparib research incorporates themes from Cediranib and Rucaparib.
Her Cancer research research also works with subjects such as
-
Immune system that connect with fields like Cytotoxic T cell,
-
DNA repair that connect with fields like DNA damage.
Her study on Chemotherapy, Recurrent Ovarian Cancer, Phases of clinical research and Progression-free survival is often connected to In patient as part of broader study in Internal medicine.
Her Oncology study also includes fields such as
-
Pembrolizumab and related Cohort,
-
Hazard ratio most often made with reference to Adverse effect.
Between 2017 and 2021, her most popular works were:
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. (131 citations)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study (122 citations)
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (119 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Ovarian cancer, Internal medicine, Oncology, Cancer research and PARP inhibitor.
Her Ovarian cancer study combines topics from a wide range of disciplines, such as Olaparib, Genome instability, Response Evaluation Criteria in Solid Tumors and Immunotherapy.
Her biological study spans a wide range of topics, including Pembrolizumab, Bevacizumab, Recurrent Ovarian Cancer and Disease.
Her research in Cancer research intersects with topics in Homologous recombination, Cancer cell, Immune system, Epigenetics and Programmed cell death.
Her PARP inhibitor study combines topics in areas such as Breast cancer and Reversion.
She interconnects Serous fluid and Absolute neutrophil count in the investigation of issues within Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
